Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services
New agreements signed with Boehringer Ingelheim Germany and Canada
Evotec AG announced that Boehringer Ingelheim (Boehringer) has extended the scope of its collaboration with Evotec. In addition to the substantial discovery programme to jointly identify and develop therapeutics acting on G-Protein Coupled Receptors (GPCRs) Boehringer research sites in Biberach (Germany) and Laval (Canada) will now collaborate with Evotec under a fee-for-service agreement.
For selected Boehringer target proteins, Evotec will apply its skills in biochemical and cellular assay development as well as in ultra-high-throughput screening (uHTS) using its proprietary FCS+plus detection platform to rapidly and accurately identify promising hit molecules from Boehringer's and Evotec's compound libraries. Active compounds will be further progressed by Boehringer to develop novel treatments for different diseases.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
MBL scientists find genes linked to human neurological disorders in sea lamprey genome - Discovery will accelerate research on Alzheimer's disease, Parkinson's disease and spinal cord injury
Merck Proposes the Creation of a Global Alliance for the Elimination of Schistosomiasis
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
